Previous Close | 1.26 |
1-Year Change | 85.29% |
6-Months Change | 40% |
3-Months Change | 15.6% |
Moving Avg (50d) | 1.2832 |
Moving Avg (200d) | 1.064 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 240.4M |
Beta (3-Years) | 1.63 |
Revenue Growth (ttm) | -7.13% |
Net Profit Margin (ttm) | -332.73% |
Return On Assets (ttm) | -66.4% |
EPS (ttm) | -1.56 |
PE Ratio (ttm) | -0.81 |
Dividend Yield | % |
Asset Description: | Nektar Therapeutics |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-10 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
1.235 | 1.197 | 1.172 | 1.134 | 1.071 | 1.008 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |